A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Patients With Influenza A Infection
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Oseltamivir (Primary) ; Pimodivir (Primary)
- Indications Influenza A virus infections
- Focus Pharmacokinetics
- Acronyms OPAL
- Sponsors Janssen Research & Development
- 30 Jun 2020 Results published in the Journal of Infectious Diseases
- 24 Apr 2018 Results of a pooled analysis from this and one other study, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
- 22 Jun 2017 Status changed from active, no longer recruiting to completed.